The most read story in cardiology this week was an article about how healthy foods lower the risk for heart disease, stroke and diabetes, followed by a study that found starting antihypertensive treatment in patients with mild hypertension was not tied to lower risk for mortality or CVD but was tied to a higher risk for adverse events.
Other popular stories included a report on the feasibility of using coronary artery calcium scoring to determine CVD risk, details on incorporating cardiac monitoring in patients with breast cancer, and the National Heart, Lung, and Blood Institute halting a trial looking at cell therapy for patients with heart failure. – by Janel Miller
Proper nutrition can change course of
coronary heart disease
, other diseases
BOSTON — Nutrition is a powerful source of cardioprotective intervention and physicians must be better about incorporating nutritional education into their treatment plans, according to a presentation at the Cardiometabolic Health Congress. Read more.
Antihypertensive treatment questionable in mild hypertension
Initiating antihypertensive treatment in patients with mild hypertension was not associated with lower risk for mortality or CVD but was associated with increased risk for adverse events, according to a study published in JAMA Internal Medicine. Read more.
Coronary artery calcium
scoring, biomarkers may help CVD risk prediction
BOSTON — Coronary artery calcium scoring and biomarker assessment appear to improve prediction of CVD risk, according to two presentations at the Cardiometabolic Health Congress. Read more.
Consideration of CV health important during breast cancer treatment
BOSTON — Breast cancer and CVD are often linked together, and therefore, oncological treatments should include CVD risks, according to a presentation at the Cardiometabolic Health Congress. Read more.
Cell therapy trial
over concerns about 'scientific foundations’
The National Heart, Lung, and Blood Institute announced it has paused the CONCERT-HF trial testing a cell therapy for patients with heart failure due to “concerns about the scientific foundations” of this trial. Read more.